Ionis Pharmaceuticals, Inc. Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value
Ionis Pharmaceuticals, Inc. (IONS) had Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value of $435.24 million as of 2021-03-31, per its 10-Q filed 2021-05-05.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue · last filed 2021-05-05
- 2021-03-31: Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value $435.24M.
- 2020-12-31: Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value $284.15M.
- 2020-09-30: Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value $218.96M.
- 2020-06-30: Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value $249.68M.
| Period end | Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value |
|---|---|
| 2021-03-31 | $435.24M 10-Q · filed 2021-05-05 |
| 2020-12-31 | $284.15M 10-K · filed 2021-02-24 |
| 2020-09-30 | $218.96M 10-Q · filed 2020-11-04 |
| 2020-06-30 | $249.68M 10-Q · filed 2020-08-05 |
| 2020-03-31 | $817.11M 10-Q · filed 2020-05-06 |
| 2019-12-31 | $375.94M 10-K · filed 2020-03-02 |
| 2019-09-30 | $486.85M 10-Q · filed 2019-11-06 |
| 2019-06-30 | $476.28M 10-Q · filed 2019-08-08 |
| 2019-03-31 | $727.65M 10-Q · filed 2019-05-09 |
| 2018-12-31 | $1.36B 10-K · filed 2019-03-01 |
| 2018-09-30 | $1.21B 10-Q · filed 2018-11-06 |
| 2018-06-30 | $1.05B 10-Q · filed 2018-08-07 |
| 2018-03-31 | $676.50M 10-Q · filed 2018-05-07 |
| 2017-12-31 | $752.57M 10-K · filed 2018-02-28 |
| 2017-09-30 | $619.01M 10-Q · filed 2017-11-07 |
| 2017-06-30 | $616.85M 10-Q · filed 2017-08-09 |
| 2017-03-31 | $621.89M 10-Q · filed 2017-05-09 |
| 2016-12-31 | $423.92M 10-K · filed 2017-03-01 |
| 2016-09-30 | $298.43M 10-Q · filed 2016-11-09 |
| 2016-06-30 | $145.50M 10-Q · filed 2016-08-09 |
| 2016-03-31 | $308.88M 10-Q · filed 2016-05-05 |
| 2015-12-31 | $540.42M 10-K · filed 2016-02-26 |
| 2015-09-30 | $384.92M 10-Q · filed 2015-11-09 |
| 2015-06-30 | $410.23M 10-Q · filed 2015-08-05 |
| 2015-03-31 | $253.64M 10-Q · filed 2015-05-05 |
| 2014-12-31 | $394.76M 10-K · filed 2015-03-02 |
| 2014-09-30 | $244.34M 10-Q · filed 2014-11-07 |
| 2014-06-30 | $206.22M 10-Q · filed 2014-08-04 |
| 2014-03-31 | $207.14M 10-Q · filed 2014-05-06 |
| 2013-12-31 | $269.87M 10-K · filed 2014-03-03 |
| 2013-09-30 | $243.69M 10-Q · filed 2013-11-05 |
| 2013-06-30 | $185.22M 10-Q · filed 2013-08-06 |
| 2013-03-31 | $114.03M 10-Q · filed 2013-05-07 |
| 2012-12-31 | $72.74M 10-K · filed 2013-02-28 |
| 2012-09-30 | $49.60M 10-Q · filed 2012-11-06 |
| 2012-06-30 | $107.27M 10-Q · filed 2012-08-06 |
| 2012-03-31 | $96.95M 10-Q · filed 2012-05-09 |
| 2011-12-31 | $162.06M 10-K · filed 2012-02-29 |
| 2011-09-30 | $168.18M 10-Q · filed 2011-11-08 |
| 2011-06-30 | $112.64M 10-Q · filed 2011-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |